There are 2949 resources available
LBA86 - Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L ES-SCLC: Characterization of long-term clinical benefit and tumour mutational burden (TMB) in CASPIAN
Presenter: Jonathan Goldman
Session: Mini Oral - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
1781MO - IMpower133: Characterisation of long-term survivors treated first-line with chemotherapy ± atezolizumab in extensive-stage small cell lung cancer
Presenter: Stephen Liu
Session: Mini Oral - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
1782MO - Health-related quality of life (HRQoL) in KEYNOTE-604: Pembrolizumab (pembro) or placebo added to etoposide and platinum (EP) as first-line therapy for ES-SCLC
Presenter: Hye Ryun Kim
Session: Mini Oral - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
1895MO - Three-year follow-up results of the MERIT trial: A Japanese phase II study of nivolumab in malignant pleural mesothelioma
Presenter: Hidetoshi Hayashi
Session: Mini Oral - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
1896MO - Volumetric PET response assessment outperforms conventional criteria in patients receiving high-dose pembrolizumab for malignant mesothelioma
Presenter: Daniel C. Christoph
Session: Mini Oral - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
1623MO - Ripretinib intra-patient dose escalation (IPDE) following disease progression provides clinically meaningful progression-free survival (PFS) in gastrointestinal stromal tumor (GIST) in phase I study
Presenter: Filip Janku
Session: Mini Oral - Sarcoma
Resources:
Abstract
Slides
Webcast
1624MO - Weekly nab-paclitaxel for progressive or symptomatic desmoid tumors: A multicenter single arm phase II trial from the Spanish Group for Research on Sarcoma (GEIS)
Presenter: Javier Martin Broto
Session: Mini Oral - Sarcoma
Resources:
Abstract
Slides
Webcast
LBA57 - MHC-II antigen presentation pathway as a predictive biomarker for sintilimab plus chemotherapy in first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC)
Presenter: Yunpeng Yang
Session: Mini Oral - NSCLC, metastatic
Resources:
Abstract
Slides
Webcast
LBA88 - Anlotinib in locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma: A randomized, double-blind, multicenter phase II trial
Presenter: Yihebali Chi
Session: Mini Oral - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
LBA80 - Outcome and prognostic factors of SARS CoV-2 infection in cancer patients: A cross-sectional study (SAKK 80/20 CaSA)
Presenter: Markus Joerger
Session: Mini Oral - SARS-CoV-2 and cancer 1
Resources:
Abstract
Slides
Webcast